and recommendation
Mesoblast Limited (MESO)
Mesoblast Limited (MESO) develops cell-based medicines.
MESO has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
MESO’s products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes.
MESO has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
- August 9, 2016 - 2:35am | Research Notes
- June 14, 2016 - 5:31pm | Research Notes
- June 14, 2016 - 6:54am | Research Notes
- June 10, 2016 - 8:11am | Research Notes
- June 7, 2016 - 9:57am | Research Notes
- April 1, 2016 - 9:44am | Research Notes, Henry'omics
- March 24, 2016 - 9:49am | Henry'omics, IP & Patents
- March 17, 2016 - 10:30am | Research Notes
- February 24, 2016 - 8:17am | Research Notes, Henry'omics
- February 22, 2016 - 8:31am | Research Notes
- February 16, 2016 - 7:17am | Research Notes, Henry'omics
- November 27, 2015 - 7:46am | Research Notes
- November 23, 2015 - 7:56am | Out and About
- November 16, 2015 - 8:45am | Research Notes
- November 13, 2015 - 9:36am | Research Notes, Financings
- October 30, 2015 - 8:34am | Research Notes, Financings